

Organised by
BRITISH JOURNAL OF
**HOSPITAL
MEDICINE**

Haematological Malignancies

Management of lymphoid
and myeloid leukaemia

Institute of Physics, London, W1

1st & 2nd June 2009

12 CPD POINTS APPLIED FOR



MA HEALTHCARE LIMITED

40 YEARS OF MEDICAL EDUCATION



Haematological M

Objectives

Haematological Malignancies

brings together leading experts in the fields of haematology, oncology, transplantation and clinical immunology to discuss the central issues and current challenges facing the management and treatment of patients with leukaemia.

It is anticipated that participants will benefit from:

- Comprehensive overviews of current and novel prognostic markers for each of the leukaemias
- Updates on the current strategies for management and treatment of children and adults with leukaemia
- Insights into promising new treatments for leukaemia, including immunotherapies, antibody treatments and gene therapies
- Understanding of the current issues and latest developments in haematopoietic stem cell transplantation
- An opportunity to share and exchange ideas with leading practitioners in the field

Who should attend?

Haematological Malignancies

will be of particular interest to the following:

- Specialists in haematology
- Specialists in oncology
- Specialists in clinical immunology
- Specialists in transplantation
- General physicians
- Nurse specialists and nurse practitioners in haematology and oncology
- Researchers in haematology, immunology and cell biology
- All trainees in these disciplines

Monday 1st June 2009

08.00-08.55	Registration and refreshments
08.55-09.00	Welcome and introduction
	ALL
09.00-09.30	Improving the outlook for adult ALL Dr Matthew Smith , Consultant Haematologist, Guy's and St Thomas' NHS Foundation Trust, London
09.30-10.00	New prognostic indicators and minimal residual disease markers Dr Nick Goulden , Consultant in Paediatric Haematology, Great Ormond Street Hospital, London
10.00-10.30	Treatment of mature B-ALL and B-lymphoblastic lymphomas Dr Robert Carr , Consultant and Honorary Senior Lecturer in Clinical and Laboratory Haematology, Guy's and St Thomas' NHS Foundation Trust, London
10.30-10.40	Discussion
10.40-11.00	Refreshments and exhibition viewing
	CLL
11.00-11.20	Identification of markers for predicting disease progression Dr Chris Pepper , Senior Lecturer, Cardiff University
11.20-11.40	The role of c-Abl in the pathogenesis of CLL Dr Ke Lin , Clinical Scientist, University of Liverpool
11.40-12.00	Managing the complications Professor Terry Hamblin , Professor of Immunohaematology, University of Southampton & Honorary Consultant, Royal Bournemouth Hospital
12.00-12.20	Current combination chemotherapies Dr Claire Dearden , Consultant Haematologist, Institute for Cancer Research and Royal Marsden Hospital, London
12.20-12.30	Discussion
12.30-13.20	Lunch and exhibition viewing
	AML
13.20-13.50	Progress in identifying molecular targets in AML Professor David Grimwade , Professor of Molecular Haematology, King's College London
13.50-14.20	Treatment options in the elderly Professor Alan Burnett , Professor of Haematology, University of Wales College of Medicine, Cardiff
14.20-14.50	Management of relapsed and refractory AML Professor Mary Frances McMullin , Professor of Clinical Haematology and Consultant Haematologist, Belfast City Hospital
14.50-15.00	Discussion
15.00-15.20	Refreshments and exhibition viewing
	CML
15.20-15.40	Diagnosis, disease phase and prognosis Dr Graeme Smith , Consultant Haematologist and Clinical Director, St James' University Hospital, Leeds
15.40-16.00	First-line therapies for children and adults in chronic stage Dr David Marin , Senior Lecturer and Honorary Consultant, Imperial College London
16.00-16.20	Mechanisms of treatment-resistance to CML Professor Richard Clark , Professor of Haematology and Consultant Haematologist, Royal Liverpool University Hospital
16.20-16.40	Second generation tyrosine kinase inhibitors Professor John Goldman , Consultant Haematologist, Hammersmith Hospital, London
16.40-17.00	Discussion
17.00	Close of day one

Malignancies

Tuesday 2nd June 2009

08.30-09.00 Registration and refreshments

PROMISING NEW TREATMENTS

09.00-09.30 Role of targeted immunoradiotherapy

Dr Peter Nicholls, Senior Lecturer in Cell and Molecular Biology, University of Kent

09.30-10.00 New treatments for acute leukaemia

Dr Brenda Gibson, Consultant Haematologist, Royal Hospital for Sick Children, Glasgow & President of the British Society of Haematology

10.00-10.30 Clinical trial updates of emerging immunotherapies

Professor Hans Stauss, Professor of Clinical Immunology, Royal Free and University College Medical School, London

10.30-10.40 Discussion

10.40-11.00 Refreshments and exhibition viewing

11.00-11.30 Novel monoclonal antibody treatments

Dr Estella Matutes, Reader in Haematological Malignancies, Institute of Cancer Research & Consultant Haematologist, Royal Marsden Hospital, London

11.30-12.00 Gene therapies: potential of RNA interference technology

Dr Elena Vigorito, Group Leader, The Babraham Institute, Cambridge

12.00-12.30 Developments in overcoming drug resistance

Dr Elaine Willmore, Senior Research Associate, Northern Institute for Cancer Research, Newcastle University

12.30-12.40 Discussion

12.40-13.30 Lunch and exhibition viewing

TRANSPLANTATION

13.30-14.00 Value of stem cell transplants in lymphoid and myeloid leukaemias

Professor Stephen McKinnon, Professor in Haematology, Royal Free and University College Medical School, London

14.00-14.30 Alternative donors and cord blood transplantation

Dr Bronwen Shaw, Institute Fellow, Institute of Cancer Research & Honorary Consultant, Royal Marsden Hospital, London

14.30-14.40 Discussion

14.40-15.00 Refreshments and exhibition viewing

15.00-15.30 The role of reduced-intensity conditioning transplants

Dr Gordon Cook, Director, Blood and Bone Marrow Transplantation & Consultant Haematologist, St James's University Hospital, Leeds

15.30-16.00 Progress in the prevention of GvHD

Dr Matthew Collin, Senior Lecturer and Honorary Consultant, Newcastle University

16.00-16.30 Relapse monitoring and management post-transplant

Dr Prem Mahendra, Consultant Haemato-oncologist, University Hospital Birmingham NHS Foundation Trust

16.30-16.45 Discussion and closing remarks

16.45 Close of conference

3 EASY WAYS TO BOOK




Complete and return the registration form overleaf



0207 501 6762



www.mahealthcareevents.co.uk



Organised by

BRITISH JOURNAL OF
**HOSPITAL
MEDICINE**



MA HEALTHCARE LIMITED

